Nanobiotix (NASDAQ:NBTX) Trading Up 6% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shot up 6% during trading on Wednesday . The stock traded as high as $43.99 and last traded at $43.99. 168,440 shares traded hands during trading, an increase of 105% from the average session volume of 82,142 shares. The stock had previously closed at $41.51.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. UBS Group boosted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Finally, Leerink Partners increased their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Performance

The firm has a 50 day moving average price of $38.80 and a 200-day moving average price of $35.73.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada grew its position in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the 4th quarter worth approximately $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter valued at approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.